# US 2017/0281802 A1 · Targeting corroles for tumor toxicity and mri

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281802 A1
- Document ID: US20170281802A1
- Status: Published application
- Kind: A1
- Application number: 15/624,228
- Filed: 2017-06-15
- Published: 2017-10-05
- Earliest claimed: 2013-05-08
- Assignees: Cedars-Sinai Medical Center
- Applicants: Cedars-Sinai Medical Center
- Inventors: Lali K. MEDINA-KAUWE
- Web page: https://patentgrep.com/patent/US20170281802A1

## CPC

- A61K 49/106: {the complex-forming compound being cyclic, e.g. DOTA}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/26: Iron; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 47/642: {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
- A61K 49/1818: {particles, e.g. uncoated or non-functionalised microparticles or nanoparticles}
- A61P 35/00: Antineoplastic agents
- A61K 9/5115: {Inorganic compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.

## Claims

### Claim 1

A method of treating cancer in a subject, comprising:
providing a composition comprising a targeted corrole nanoparticle; and
administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the targeted corrole nanoparticle includes manganese (Mn), iron (Fe), and/or gallium (Ga).

### Claim 3 (depends on 1)

The method of claim 1, wherein the nanoparticle is the combination of a corrole compound with a HerPBK10 molecule.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nanoparticle is HerMn, HerFe, or HerGa.

### Claim 5

A method of imaging a condition in a subject, comprising:
providing a composition comprising a targeted corrole nanoparticle;
administering an effective amount of the targeted corrole nanoparticle to the subject; and
imaging the condition in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the targeted corrole nanoparticle includes manganese (Mn), iron (Fe), and/or gallium (Ga).

### Claim 7 (depends on 5)

The method of claim 5, wherein the nanoparticle is the combination of a corrole compound with a HerPBK10 molecule.

### Claim 8 (depends on 5)

The method of claim 5, wherein the nanoparticle is HerMn, HerFe, or HerGa.

### Claim 9 (depends on 5)

The method of claim 5, wherein MRI is used to image the condition.

### Claim 10 (depends on 5)

The method of claim 5, wherein the condition is cancer.

### Claim 11

A composition comprising a targeted corrole nanoparticle; and an acceptable carrier or excipient.

### Claim 12

The method of claim erein the targeted corrole nanoparticle is HerMn, HerFe, or HerGa.

### Claim 13 (depends on 11)

The method of claim 11, wherein the targeted corrole nanoparticle is targeted to a tumor cell type.

### Claim 14 (depends on 11)

The method of claim 11, wherein the targeted corrole nanoparticle is HerMn, HerFe, or HerGa.

### Claim 15 (depends on 1)

The method of claim 1.1, wherein the targeted corrole nanoparticle is targeted to a tumor cell type.